Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts give Precision BioSciences a “Moderate Buy” consensus: Four of five covering brokerages rate the stock a buy, while one recommends selling. The average 12-month price target is $32.25.
• DTIL opened at $6.63, with a market capitalization of approximately $183 million and a 52-week trading range of $3.53 to $9.62.
• Quarterly results fell short of expectations: Precision BioSciences reported an adjusted loss of $1.26 per share versus the $0.80 loss analysts expected, alongside a negative net margin of 96.73%. Institutional investors own about 38% of the company.

Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $32.25.

DTIL has been the topic of several research reports. HC Wainwright restated a "buy" rating on shares of Precision BioSciences in a report on Monday, August 3rd. Oppenheimer initiated coverage on Precision BioSciences in a report on Tuesday, June 9th. They issued an "outperform" rating and a $20.00 target price for the company. Wall Street Zen downgraded Precision BioSciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Precision BioSciences in a research note on Wednesday, August 5th.

Precision BioSciences Price Performance

Precision BioSciences stock opened at $6.63 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82. The stock has a market cap of $182.99 million, a price-to-earnings ratio of -2.37 and a beta of 1.24. The firm has a 50-day moving average of $7.67 and a two-hundred day moving average of $7.08. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $9.62.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. On average, research analysts forecast that Precision BioSciences will post -3.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. HBK Sorce Advisory LLC bought a new stake in shares of Precision BioSciences in the 4th quarter valued at about $38,000. Miller Financial Services LLC boosted its stake in shares of Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company's stock valued at $62,000 after purchasing an additional 5,000 shares in the last quarter. Quantinno Capital Management LP purchased a new position in Precision BioSciences during the first quarter valued at approximately $104,000. Engineers Gate Manager LP bought a new position in Precision BioSciences in the second quarter worth approximately $164,000. Finally, Bank of America Corp DE raised its stake in Precision BioSciences by 167.6% in the first quarter. Bank of America Corp DE now owns 27,416 shares of the company's stock worth $151,000 after buying an additional 17,172 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company's stock.

Precision BioSciences Company Profile

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.